Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound

Core Insights - The FDA approved Eli Lilly's weight-loss drug Zepbound for treating moderate-to-severe obstructive sleep apnea in adults with obesity, raising concerns for companies like ResMed and Inspire Medical Systems that currently provide treatment devices [6][4] - ResMed's Chief Medical Officer indicated that weight-loss medications could be used alongside existing therapies, suggesting a potential shift in treatment approaches for sleep apnea [4][6] - Despite a recent decline in stock prices, ResMed shares have increased by approximately 33% this year, while Inspire Medical Systems shares have decreased by 9% in 2024 [6][4] Company Impact - ResMed's shares fell about 4% following the FDA's decision, but the company has seen significant growth in stock value this year [6][4] - Inspire Medical Systems experienced a 1.4% drop in shares, reflecting investor concerns about competition from new weight-loss drugs [6][4] - Analysts show mixed ratings for both companies, with ResMed receiving three "buy" and four "hold" ratings, while Inspire Medical Systems has seven "buy" and two "hold" ratings [6][4]